Search research articles
Contact Us
Filters
Showing results (391-400 of 743) with videos related to
Page
of 75
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 21, 2016
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity
Alexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Cancers
|
February 11, 2023
P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma
Ishani Banik, Adhideb Ghosh, Erin Beebe, et al.
Clinical Nuclear Medicine
|
September 26, 2024
18 F-FDG PET/CT for Detection of Immunotherapy-Induced Hypophysitis-A Case-Control Study
Alessa Fischer, Julia M Martínez-Gómez, Joanna Mangana, et al.
The Journal of Clinical Investigation
|
May 1, 2019
SMAD signaling promotes melanoma metastasis independently of phenotype switching
Eylul Tuncer, Raquel R Calçada, Daniel Zingg, et al.
American Journal of Therapeutics
|
January 14, 2014
Treatment algorithms in stage IV melanoma
Enrique Espinosa, Jean-Jacques Grob, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 20, 2022
Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival
Stefanos Voglis, Valentina Schaller, Timothy Müller, et al.
Melanoma Research
|
February 28, 2018
Sarcoid-like reactions in patients receiving modern melanoma treatment
Florentia Dimitriou, Anna L Frauchiger, Mirjana Urosevic-Maiwald, et al.
The Lancet. Oncology
|
June 6, 2013
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Caroline Robert, Reinhard Dummer, Ralf Gutzmer, et al.
Oncogene
|
April 3, 2020
Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth
Rexhep Uka, Christian Britschgi, Anja Krättli, et al.
RNA Biology
|
August 22, 2022
The A to I editing landscape in melanoma and its relation to clinical outcome
Austeja Amweg, Marina Tusup, Phil Cheng, et al.
Page
of 75
Search research articles
Search
Showing results (391-400 of 743) with videos related to
Sort By:
Page
of 75
European Journal of Cancer (Oxford, England : 1990)
|
January 21, 2016
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity
Alexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Cancers
|
February 11, 2023
P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma
Ishani Banik, Adhideb Ghosh, Erin Beebe, et al.
Clinical Nuclear Medicine
|
September 26, 2024
18 F-FDG PET/CT for Detection of Immunotherapy-Induced Hypophysitis-A Case-Control Study
Alessa Fischer, Julia M Martínez-Gómez, Joanna Mangana, et al.
The Journal of Clinical Investigation
|
May 1, 2019
SMAD signaling promotes melanoma metastasis independently of phenotype switching
Eylul Tuncer, Raquel R Calçada, Daniel Zingg, et al.
American Journal of Therapeutics
|
January 14, 2014
Treatment algorithms in stage IV melanoma
Enrique Espinosa, Jean-Jacques Grob, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 20, 2022
Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival
Stefanos Voglis, Valentina Schaller, Timothy Müller, et al.
Melanoma Research
|
February 28, 2018
Sarcoid-like reactions in patients receiving modern melanoma treatment
Florentia Dimitriou, Anna L Frauchiger, Mirjana Urosevic-Maiwald, et al.
The Lancet. Oncology
|
June 6, 2013
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Caroline Robert, Reinhard Dummer, Ralf Gutzmer, et al.
Oncogene
|
April 3, 2020
Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth
Rexhep Uka, Christian Britschgi, Anja Krättli, et al.
RNA Biology
|
August 22, 2022
The A to I editing landscape in melanoma and its relation to clinical outcome
Austeja Amweg, Marina Tusup, Phil Cheng, et al.
Page
of 75